Lupin has informed that it enclosed a Press Release as regards, receipt of approval from the U.S. FDA for the Company’s Abbreviated New Drug Applications for Liraglutide Injection Single-Patient-Use Prefilled Pens and Glucagon for Injection vials.
The above information is a part of company’s filings submitted to BSE.